8月20日，戴维医疗今日收盘14.82元，下跌1.53%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到102.30倍，总市值42.68亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13戴维医疗102.3074.543.5842.68亿行业平均 59.3254.705.08121.09亿行业中值39.9739.752.9659.06亿1九安医疗11.6111.740.91195.93亿2英科医疗 15.3516.551.37242.47亿3山东药玻16.3716.421.88154.82亿4新华医疗16.4015.201.34105.14亿5奥美医疗 17.1116.761.7661.81亿6九强生物17.8316.582.1888.30亿7振德医疗18.0617.021.1565.55亿8康德莱 18.2418.261.5139.31亿9奥泰生物18.5219.531.5059.06亿10维力医疗18.6319.902.3443.67亿11鱼跃医疗 20.4920.102.77362.90亿12安图生物20.9620.012.69238.97亿 来源：金融界 宁波戴维医疗器械股 ...

Core Viewpoint - David Medical's stock closed at 15.05 yuan, with a PE ratio of 103.88 times, significantly higher than the industry average of 59.49 times, indicating potential overvaluation in the context of its financial performance [1][2] Company Summary - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators, warming devices, jaundice treatment equipment, and various monitoring devices [1] - The company has received multiple accolades, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology, and has been awarded "Zhejiang Province Famous Trademark" and "AAA Credit Rating Enterprise" [1] Financial Performance - For Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% from the previous year, with a gross margin of 57.13% [2] - The company's PE ratio (TTM) stands at 103.88, while the industry average is 59.49, indicating a significant premium on its valuation compared to peers [2]

最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13戴维医疗102.6474.793.5942.83亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科医疗 15.6416.861.39247.04亿3山东药玻16.2816.331.87154.02亿4新华医疗16.6315.411.36106.59亿5奥美医疗 17.1216.781.7661.87亿6振德医疗17.3816.381.1163.10亿7九强生物17.7016.462.1787.65亿8康德莱 18.0418.051.4938.87亿9维力医疗18.5219.782.3343.40亿10奥泰生物18.7119.731.5159.67亿11鱼跃医疗 20.2019.812.73357.68亿12安图生物20.8619.922.68237.88亿 8月15日，戴维医疗今日收盘1 ...

Core Viewpoint - David Medical's stock closed at 15.24 yuan, down 2.62%, with a rolling PE ratio of 105.19 times, significantly higher than the industry average of 57.48 times [1][2] Company Summary - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, including incubators, warming devices, jaundice treatment equipment, and various monitoring devices [1] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology, and has been awarded "Zhejiang Province Famous Trademark" and "AAA Credit Rating Enterprise" [1] Financial Performance - In the latest quarterly report for Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% [2] - The sales gross margin for the same period was 57.13% [2] Industry Comparison - David Medical ranks 105th in terms of PE ratio within the medical device industry, where the median PE ratio is 40.95 times [1][2] - The industry average PE ratio is 57.48 times, indicating that David Medical's valuation is significantly above the industry norms [2]

最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13戴维医疗108.0278.713.7845.07亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0516.231.34237.81亿3山东药玻16.1716.221.86152.96亿4新华医疗16.9415.701.38108.60亿5振德医疗 17.3716.371.1063.04亿6奥美医疗17.5417.191.8063.39亿7九强生物17.9216.672.2088.77亿8康德莱 18.7518.761.5540.40亿9维力医疗18.7920.082.3644.05亿10奥泰生物19.3120.361.5661.58亿11鱼跃医疗 20.2319.842.73358.29亿12安图生物21.1920.232.72241.60亿 8月12日，戴维医疗今日收盘1 ...

8月11日，戴维医疗今日收盘15.25元，上涨10.03%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到105.26倍，创388天以来新低，总市值43.92亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13戴维医疗105.2676.703.6843.92亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗 17.1715.911.40110.05亿6奥美医疗17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德莱 18.3218.341.5239.49亿9维力医疗18.6219.892.3443.64亿10奥泰生物1 ...

Group 1 - The stock price of David Medical reached 14.11 yuan as of August 4, 2025, with an increase of 0.03 yuan from the previous trading day [1] - The company operates in the medical device sector, focusing on the research and manufacturing of infant care equipment, including incubators and radiant warmers for newborns [1] - The latest data indicates a total market capitalization of 4.064 billion yuan and a price-to-earnings ratio of 45.02 [1] Group 2 - The HLD series medical isolation pad, referred to as the "baby nest," provides tactile stimulation and a sense of security for infants, effectively regulating heart rate, respiratory rate, and improving sleep quality [1] - On August 4, there was a net outflow of 22.0897 million yuan in main funds, accounting for 1.09% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow was 18.7868 million yuan, representing 0.93% of the circulating market value [1]

Group 1 - The core stock price of David Medical as of July 31, 2025, closed at 14.21 yuan, down 3.00% from the previous trading day, with a trading volume of 370 million yuan [1] - The stock experienced significant volatility during the day, with a high of 14.98 yuan and a low of 14.21 yuan, resulting in a fluctuation of 5.26% [1] - David Medical specializes in the research, production, and sales of medical devices, primarily focusing on neonatal medical equipment such as incubators and radiant warmers [1] Group 2 - On July 31, the stock showed rapid fluctuations, with a rebound of over 2% within 5 minutes in the morning session, followed by a quick decline of over 2% within the next 5 minutes, indicating active market trading [1] - The net outflow of main funds was 9.0994 million yuan, accounting for 0.45% of the circulating market value, suggesting market divergence regarding the short-term outlook of the stock [1]

7月31日，戴维医疗今日收盘14.21元，下跌3.00%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到98.09倍，总市值40.92亿元。 资金流向方面，7月31日，戴维医疗主力资金净流出909.94万元，近5日总体呈流入状态，5日共流入 4271.27万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13戴维医疗98.0971.473.4340.92亿行业平均 54.8949.974.71114.46亿行业中值37.0636.862.6754.89亿1九安医疗10.9311.060.86184.50亿2英科医疗 14.2315.351.27224.88亿3新华医疗15.7214.571.28100.77亿4山东药玻15.9516.001.83150.91亿5奥美医疗 16.2315.911.6758.64亿6振德医疗16.2415.301.0358.94亿7康德莱17.1117.121.4236.87亿8九强生物 17.3416.132.1285.89亿9维力医疗17.4318.622.1940.86亿10奥泰生物17.8318.801.4456.86亿11鱼跃医疗 19.741 ...

Group 1: Policy Impact on Industry - The implementation of the child-rearing subsidy policy is expected to significantly lower family child-rearing costs and enhance birth intentions, particularly benefiting the maternal and infant industry and dairy sectors [2][3] - The national child-rearing subsidy will provide annual cash support of 3,600 yuan per child for families with children under three years old, starting from January 1, 2025, which is projected to benefit over 20 million families annually [1][2] Group 2: Market Growth Projections - The Chinese baby and toddler market is currently in a "golden period" of growth, with a market size expected to reach 4.2 trillion yuan in 2024, surpassing 5 trillion yuan by 2025, and potentially reaching 10 trillion yuan by 2030 [2] - The policy and consumption upgrades are anticipated to drive the industry into becoming the next trillion-level blue ocean market [2] Group 3: Key Companies in the Sector - Aiyingshi focuses on providing maternal and infant products for families with children aged 0-6, with a strong market presence in East China [3] - Haiziwang is a leading retailer in the maternal and infant goods sector, offering a wide range of products for families with children up to 6 years old [3] - Beingmate is a domestic leader in infant formula, recognized for its safety traceability system [3] - Huhulawa specializes in pediatric respiratory treatments and has a high market share in children's medication [4] - Xibu Muye operates in one of China's major pastoral areas and produces infant formula [3] - Huangshi Group is a champion in the water buffalo milk segment, developing specialized milk products for children [4] - David Medical is a leading company in infant care equipment, focusing on the development and production of essential medical devices for newborns [4]